148 related articles for article (PubMed ID: 35614466)
1. Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study.
Johnson B; Flensburg OL; Capusan AJ
Subst Abuse Treat Prev Policy; 2022 May; 17(1):40. PubMed ID: 35614466
[TBL] [Abstract][Full Text] [Related]
2. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
Johnson B; Monwell B; Capusan AJ
Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
[TBL] [Abstract][Full Text] [Related]
3. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
Tompkins CNE; Neale J; Strang J
J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
[TBL] [Abstract][Full Text] [Related]
4. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
[TBL] [Abstract][Full Text] [Related]
5. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
[TBL] [Abstract][Full Text] [Related]
6. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
Neale J; Tompkins CNE; Strang J
Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
[TBL] [Abstract][Full Text] [Related]
7. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
8. Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use Disorder.
Parkin S; Neale J; Strang J
Subst Use Misuse; 2023; 58(13):1696-1706. PubMed ID: 37571999
[No Abstract] [Full Text] [Related]
9. Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin.
Neale J; Tompkins CNE; McDonald R; Strang J
Drug Alcohol Depend; 2018 Aug; 189():1-7. PubMed ID: 29857327
[TBL] [Abstract][Full Text] [Related]
10. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.
Barnett A; Pienaar K; Lubman DI; Arunogiri S; Phan V; Hayes V; Lintzeris N; Savic M
Int J Drug Policy; 2024 May; 127():104399. PubMed ID: 38636315
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
12. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
13. A Case of Acute Opioid Withdrawal after Liposuction Surgery in a Patient on Extended-release Buprenorphine.
Bobb R; Malayala SV; Papudesi BN; Potluri D
J Addict Med; 2023 Sep-Oct 01; 17(5):621-623. PubMed ID: 37788623
[TBL] [Abstract][Full Text] [Related]
14. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
[TBL] [Abstract][Full Text] [Related]
15. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
Soyka M; Groß G
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
[TBL] [Abstract][Full Text] [Related]
16. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification.
Sobel BF; Sigmon SC; Walsh SL; Johnson RE; Liebson IA; Nuwayser ES; Kerrigan JH; Bigelow GE
Drug Alcohol Depend; 2004 Jan; 73(1):11-22. PubMed ID: 14687955
[TBL] [Abstract][Full Text] [Related]
17. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
Neale J; Tompkins CNE; Strang J
Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
[TBL] [Abstract][Full Text] [Related]
18. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
[TBL] [Abstract][Full Text] [Related]
19. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
20. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
Cheng A; Badolato R; Segoshi A; McDonald R; Malone M; Vasudevan K; Badiei B; Sugarman A; Macdonald R; Mangat J; Giftos J; Lee JD; Tofighi B
Addict Sci Clin Pract; 2022 Jan; 17(1):4. PubMed ID: 35093164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
